Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crispr Therapeutics Ag (NQ: CRSP )

47.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today
The returns haven't been half bad, to say the least. 
Via The Motley Fool
Crispr: A Fallen Angel In Gene Editing
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review
It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields. 
Via Investor's Business Daily
Exposures Fossil Fuels
BZ Chart Of The Day: Is Crisper Therapeutics About To Rally?
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) may be form... 
Via Benzinga
Analyzing CRISPR Therapeutics's Unusual Options Activity
Shares of CRISPR Therapeutics (NASDAQ:CRSP) saw some unus... 
Via Benzinga
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
Via Benzinga
Exposures COVID-19
50 Biggest Movers From Yesterday
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today
Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. 
Via InvestorPlace
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
Via Benzinga
Why CRISPR Therapeutics Stock Is Sinking Today
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Tumbling Today
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-... 
Via Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Why CRISPR Therapeutics Stock Fell 10.4% Last Month
CRISPR Therapeutics stock is now down roughly 33% across 2021's trading. 
Via The Motley Fool
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated. 
Via The Motley Fool
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
3 Explosive Biotech Stocks That Could 10X in 10 Years
They're leaders in therapeutic areas with massive growth potential. 
Via The Motley Fool
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover. 
Via The Motley Fool
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
Vertex plans to work more closely on CRISPR gene editing with a small privately-held biotech. 
Via The Motley Fool
Could CRISPR Therapeutics Stock Help You Retire a Millionaire?
A crowded field could take years to thin out. 
Via The Motley Fool
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Exposures COVID-19 Interest Rates Product Safety
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
Updated Clinical and Financial Data Make the Case for CRISPR Therapeutics
Currently trading at a very reasonable multiple, CRSP stock is an undeniable buy. 
Via InvestorPlace
Why CRISPR Therapeutics Stock Fell 25.2% in July
The stock dropped roughly $40 per share over the course of the month. 
Via The Motley Fool
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
Better Buy: Vertex vs. CRISPR
Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.